Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators

Journal of the Neurological Sciences

Volumn 259, Issue 1-2, 2007, Pages 79-84

  Yong, V Wee ^a   Zabad, Rana K ^a   Agrawal, Smriti ^a   Goncalves DaSilva, Angelika ^a   Metz, Luanne M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

EAE; Interferon beta; Metalloproteinases; Minocycline; Multiple sclerosis

Indexed keywords

BB 1101; BETA INTERFERON; GELATINASE B; GLATIRAMER; ILOMASTAT; IMMUNOMODULATING AGENT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; PENICILLAMINE; UK 221316; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG UTILIZATION; HUMAN; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOLOGIC FACTORS; MATRIX METALLOPROTEINASES; MULTIPLE SCLEROSIS;

EID: 34447104602     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.11.021     Document Type: Article

References (58)

1. Weaver A., Goncalves da Silva A., Nuttall R.K., Edwards D.R., Shapiro S.D., Rivest S., et al. An elevated matrix metalloproteinase in experimental autoimmune encephalomyelitis is protective by affecting Th1/Th2 polarization. FASEB J 19 (2005) 1668-1670
2. Yong V.W., Power C., Forsyth P., and Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2 (2001) 502-511
3. Kieseier B.C., Seifert T., Giovannoni G., and Hartung H.P. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 53 (1999) 20-25
4. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6 (2005) 931-944
5. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 94 (1997) 590-598
6. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., and Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23 (1997) 406-415
7. Lindberg R.L., De Groot C.J., Montagne L., Freitag P., van Der Valk P., Kappos L., et al. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124 (2001) 1743-1753
8. Vos C.M., van Haastert E.S., de Groot C.J., van der Valk P., and de Vries H.E. Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol 138 (2003) 106-114
9. Lichtinghagen R., Seifert T., Kracke A., Marckmann S., Wurster U., and Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 99 (1999) 19-26
10. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., and Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122 (1999) 191-197 [see comments]
11. Waubant E., Goodkin D.E., Gee L., Bacchetti P., Sloan R., Stewart T., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53 (1999) 1397-1401 [see comments]
12. Waubant E., Goodkin D., Bostrom A., Bacchetti P., Hietpas J., Lindberg R., et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60 (2003) 52-57
13. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121 (1998) 2327-2334
14. Liuzzi G.M., Trojano M., Fanelli M., Avolio C., Fasano A., Livrea P., et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 8 (2002) 222-228
15. Fainardi E., Castellazzi M., Bellini T., Manfrinato M.C., Baldi E., Casetta I., et al. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 12 (2006) 294-301
16. Correale J., and Bassani Molinas Mde L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 140 (2003) 198-209
17. Lichtinghagen R., Seifert T., Kracke A., Marckmann S., Wurster U., and Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 99 (1999) 19-26
18. Fiotti N., Zivadinov R., Altamura N., Nasuelli D., Bratina A., Tommasi M.A., et al. MMP-9 microsatellite polymorphism and multiple sclerosis. J Neuroimmunol 152 (2004) 147-153
19. Nelissen I., Vandenbroeck K., Fiten P., Hillert J., Olsson T., Marrosu M.G., et al. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J Neuroimmunol 105 (2000) 58-63
20. Kouwenhoven M., Ozenci V., Gomes A., Yarilin D., Giedraitis V., Press R., et al. Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes. J Autoimmun 16 (2001) 463-470
21. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., and Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 50 (2001) 443-451
22. Bar-Or A., Nuttall R., Duddy M., Alter A., Pennington C., Bourgoin P., et al. Analyses of all MMP members in leukocytes emphasize monocytes as major inflammatory mediators in MS. Brain 126 (2003) 2738-2749
23. Kanesaka T., Mori M., Hattori T., Oki T., and Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 77 2 (2006) 185-188
24. Sastre-Garriga J., Comabella M., Brieva L., Rovira A., Tintore M., and Montalban X. Decreased MMP-9 production in primary progressive multiple sclerosis patients. Mult Scler 10 (2004) 376-380
25. Avolio C., Ruggieri M., Giuliani F., Liuzzi G.M., Leante R., Riccio P., et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136 (2003) 46-53
26. Opdenakker G., Nelissen I., and Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2 12 (2003) 747-756
27. Abraham M., Shapiro S., Karni A., Weiner H.L., and Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol 163 (2005) 157-164
28. Agrawal S., Abderson P., Durbeej M., van Rooijen N., Ivars F., Opdenakker G., et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 203 (2006) 1007-1019
29. Hansen H., Nuttall R.K., Edwards D.R., and Owens T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 173 (2004) 5209-5218
30. Clements J.M., Cossins J.A., Wells G.M., Corkill D.J., Helfrich K., Wood L.M., et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-α inhibitor. J Neuroimmunol 74 (1997) 85-94
31. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M., Schweitzer T., et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121 (1998) 159-166
32. Pagenstecher A., Stadler A.K., Kincaid A.L., Shapiro S.D., and Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 152 (1998) 729-741
33. Nygardas P.T., and Hinkkanen A.E. Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol 128 (2002) 245-254
34. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104 (1999) 1507-1515
35. Esparza J., Kruse M., Lee J., Michaud M., and Madri J.A. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J 18 (2004) 1682-1691
36. Gijbels K., Galardy R.E., and Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94 (1994) 2177-2182
37. Graesser D., Mahooti S., and Madri J.A. Distinct roles for matrix metalloproteinase-2 and alpha4 integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis. J Neuroimmunol 109 (2000) 121-131
38. Hewson A.K., Smith T., Leonard J.P., and Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 44 (1995) 345-349
39. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C.C., et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72 2 (1997) 155-161
40. Graesser D., Mahooti S., Haas T., Davis S., Clark R.B., and Madri J.A. The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis. Lab Invest 78 (1998) 1445-1458
41. Norga K., Paemen L., Masure S., Dillen C., Heremans H., Billiau A., et al. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor d-penicillamine. Inflamm Res 44 (1995) 529-534
42. Yong V.W., Wells J., Giuliani F., Casha S., Power C., and Metz L.M. The promise of minocycline in neurology. Lancet Neurol 3 (2004) 744-751
43. Brundula V., Rewcastle B., Metz L., Bernard C.C., and Yong V.W. Targeting leukocyte MMPs and transmigration: minocycline as a novel therapeutic for multiple sclerosis. Brain 125 (2002) 1297-1308
44. Metz L.M., Zhang Y., Yeung M., Patry D.G., Bell R.B., Stoian C.A., et al. Minocycline reduces gadolinium-enhancing MRI lesions in multiple sclerosis. Ann Neurol 55 (2004) 756
45. Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, et. al. The clinical response to minocycline in MS is accompanied by immune changes. Mult Scler in press.
46. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Williams G., and Yong V.W. Interferon-β decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40 (1996) 853-863
47. Leppert D., Waubant E., Burk M.R., Oksenberg J.R., and Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vivo migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40 (1996) 846-852
48. Yong V.W. Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology 59 (2002) 802-808
49. Bartholome E.J., Van Aelst I., Koyen E., Kiss R., Willems F., Goldman M., et al. Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. J Interferon Cytokine Res 21 (2001) 495-501
50. Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg 108 2 (2006) 124-128
51. Trojano M., Avolio C., Liuzzi G.M., Ruggieri M., Defazio G., Liguori M., et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53 (1999) 1402-1408
52. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., and Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 50 (2001) 443-451
53. Avolio C., Filippi M., Tortorella C., Rocca M.A., Ruggieri M., Agosta F., et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 11 (2005) 441-446
54. Karabudak R., Kurne A., Guc D., Sengelen M., Canpinar H., and Kansu E. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. J Neurol 251 3 (2004) 279-283
55. Nelissen I., Martens E., Van den Steen P.E., Proost P., Ronsse I., and Opdenakker G. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain 126 (2003) 1371-1381
56. Giuliani F., Fu S., Metz L.M., and Yong V.W. Effective combination of minocycline and interferon-β in a model of multiple sclerosis. J Neuroimmunol 165 (2005) 83-91
57. Rosenberg G.A. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8 (2002) 586-595
58. Rosenberg G.A. Matrix metalloproteinases in multiple sclerosis: is it time for a treatment trial?. Ann Neurol 50 (2001) 431-433